Phase 3
N/A
N/A
N/A
N/A
Not Enrolling
Both
Pheochromocytoma, Neuroblastoma
Both
Pheochromocytoma, Neuroblastoma
Trial Information
Inclusion Criteria
- Subject must either have:
1. known or suspected neuroblastoma OR
2. known or suspected phaeochromocytoma
- Subjects are not eligible for the study if they have any clinically active, serious,
life-threatening disease other than neuroblastoma or phaeochromocytoma with a life
expectancy of less than 30 days or where participation in the study might compromise
the management of the subject or other reason that in the judgement of the
investigator(s) makes the subject unsuitable for participation in the study.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
- To demonstrate that 123I-mIBG planar scintigraphy is sensitive and specific in confirming or excluding the diagnoses of neuroblastoma and phaeochromocytoma.
Principal Investigator
Diane McCaul
Investigator Role:
Study Director
Investigator Affiliation:
GE Healthcare
Authority:
United States: Food and Drug Administration
Study ID:
MBG308
NCT ID:
NCT00126412
Start Date:
July 2005
Completion Date:
Related Keywords:
- Pheochromocytoma
- Neuroblastoma
- Phaeochromocytoma
- Neuroblastoma
- diagnosis
- 123I-mIBG
- Neuroblastoma
- Pheochromocytoma
Name | Location |
|---|---|
| GE Healthcare | Princeton, New Jersey 08540 |
